---
document_datetime: 2024-03-01 11:34:01
document_pages: 20
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/aldara-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf
document_name: aldara-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf
version: success
processing_time: 12.9441925
conversion_datetime: 2025-12-22 13:49:16.778935
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## Aldara

Procedural steps taken and scientific information after the authorisation

| Application number   | Scope                                                                                            | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary                           |
|----------------------|--------------------------------------------------------------------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|-----------------------------------|
| N/0090               | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification) | 29/02/2024                          |                                             | PL                               |                                   |
| PSUSA/1729/ 202301   | Periodic Safety Update EU Single assessment - imiquimod                                          | 28/09/2023                          | n/a                                         |                                  | PRAC Recommendation - maintenance |

1 Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions are issued for all other procedures.

2 A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures.

3 SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet).

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

| IA/0088   | A.7 - Administrative change - Deletion of manufacturing sites                                                                                                                                                                                                                                                                                                                                                                                                                                              | 05/07/2023   |            | Annex II and PL   |             |
|-----------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|------------|-------------------|-------------|
| T/0086    | Transfer of Marketing Authorisation                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | 28/10/2022   | 21/11/2022 | SmPC and PL       |             |
| N/0085    | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                                                                                                                                                                                                                                                                                                                                           | 08/12/2021   | 13/04/2022 | PL                |             |
| IA/0084   | A.7 - Administrative change - Deletion of manufacturing sites                                                                                                                                                                                                                                                                                                                                                                                                                                              | 27/08/2021   | n/a        |                   |             |
| IB/0081/G | This was an application for a group of variations. B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor changes to an approved test procedure B.I.a.2.e - Changes in the manufacturing process of the AS - Minor change to the restricted part of an ASMF B.I.b.1.d - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Deletion of a non- significant specification parameter (e.g. deletion of parameter) | 26/05/2021   | n/a        |                   | an obsolete |
| IA/0083/G | This was an application for a group of variations. A.5.b - Administrative change - Change in the name and/or address of a manufacturer/importer of the finished product, including quality control sites (excluding manufacturer for batch release)                                                                                                                                                                                                                                                        | 16/04/2021   | n/a        |                   |             |

<div style=\"page-break-after: always\"></div>

|                    | B.II.c.1.c - Change in the specification parameters and/or limits of an excipient - Deletion of a non- significant specification parameter (e.g. deletion of an obsolete parameter) B.I.b.1.d - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Deletion of a non- significant specification parameter (e.g. deletion of an obsolete parameter)   |            |            |                            |                                                                                                                                           |
|--------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|----------------------------|-------------------------------------------------------------------------------------------------------------------------------------------|
| IA/0082            | A.7 - Administrative change - Deletion of manufacturing sites                                                                                                                                                                                                                                                                                                                                             | 10/03/2021 | 13/04/2022 | Annex II, Labelling and PL |                                                                                                                                           |
| IB/0080            | B.II.d.2.z - Change in test procedure for the finished product - Other variation                                                                                                                                                                                                                                                                                                                          | 29/01/2021 | n/a        |                            |                                                                                                                                           |
| PSUSA/1729/ 202001 | Periodic Safety Update EU Single assessment - imiquimod                                                                                                                                                                                                                                                                                                                                                   | 15/10/2020 | 09/12/2020 | PL                         | Refer to Scientific conclusions and grounds recommending the variation to terms of the Marketing Authorisation(s)' for PSUSA/1729/202001. |
| N/0079             | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                                                                                                                                                                                                                                          | 07/10/2020 | 09/12/2020 | Labelling                  |                                                                                                                                           |
| IB/0077/G          | This was an application for a group of variations. A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or manufacturer of a novel excipient B.I.b.2.e - Change in test procedure for AS or                                                            | 25/06/2020 | 09/12/2020 | Annex II and PL            |                                                                                                                                           |

<div style=\"page-break-after: always\"></div>

<!-- image -->

| starting material/reagent/intermediate changes to a test procedure or addition) for the AS material/intermediate B.I.b.2.e - Change in test starting material/reagent/intermediate changes to a test procedure or addition) for the AS material/intermediate B.II.b.1.b - Replacement manufacturing site for the site B.II.b.1.e - Replacement manufacturing site for the manufacturing operation(s) release, batch control, packaging, for non-sterile B.II.b.2.c.1 - Change to arrangements and quality Replacement or addition responsible for importation Not including batch control/testing B.II.b.3.a - Change in the the finished or intermediate in the manufacturing process B.II.b.3.z - Change in the the finished or intermediate B.II.b.3.a - Change in the the finished or intermediate in the manufacturing process B.II.d.2.d - Change in test   |
|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

<div style=\"page-break-after: always\"></div>

|             | replacement or addition) - Change in the specification parameters limits of the immediate packaging of the product - Tightening of specification limits                                                                                                                                                                                                                            |            |            |                 | (including B.II.e.2.a and/or finished   |
|-------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-----------------|-----------------------------------------|
| IA/0076/G   | This was an application for a group of variations. B.II.b.2.a - Change to importer, batch release arrangements and quality control testing of the FP - Replacement/addition of a site where batch control/testing takes place B.II.b.2.a - Change to importer, batch release arrangements and quality control testing of the FP - Replacement/addition of a site where batch place | 14/08/2019 | n/a        |                 | control/testing takes                   |
| IAIN/0074/G | application for a group of variations. B.II.b.1.a - Replacement or addition of a manufacturing site for the FP - Secondary packaging site B.II.b.2.c.1 - Change to importer, batch release arrangements and quality control testing of the FP - Replacement or addition of a manufacturer responsible for importation and/or batch release - Not including batch control/testing   | 21/11/2018 | 12/06/2019 | Annex II and PL | This was an                             |
| IB/0073/G   | This was an application for a group of variations. B.I.b.1.b - Change in the specification parameters and/or limits of an AS, starting                                                                                                                                                                                                                                             | 10/09/2018 | n/a        |                 |                                         |

<div style=\"page-break-after: always\"></div>

|                    | specification limits B.I.b.2.e - Change in test procedure for AS or starting material/reagent/intermediate - Other changes to a test procedure (including replacement or addition) for the AS or a starting material/intermediate B.I.b.2.e - Change in test procedure for AS or starting material/reagent/intermediate - Other changes to a test procedure (including replacement or addition) for the AS or a starting material/intermediate B.I.d.1.b.1 - Stability of AS - Change in the storage conditions - Change to more restrictive storage conditions of the AS   |            |            |                        |                                   |
|--------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------------------------|-----------------------------------|
| IB/0072            | C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation                                                                                                                                                                                                                                                                                                                                                                                                                                                                              | 29/06/2018 | 12/06/2019 | SmPC, Labelling and PL |                                   |
| N/0071             | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                                                                                                                                                                                                                                                                                                                                                                                                            | 08/03/2018 | 12/06/2019 | PL                     |                                   |
| PSUSA/1729/ 201701 | Periodic Safety Update EU Single assessment - imiquimod                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     | 28/09/2017 | n/a        |                        | PRAC Recommendation - maintenance |
| IA/0069            | A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or manufacturer of a novel excipient                                                                                                                                                                                                                                                                                                                                | 14/02/2017 | n/a        |                        |                                   |

<div style=\"page-break-after: always\"></div>

| II/0067   | Update of sections 4.2, 4.4 and 5.1 of the SmPC in order to add data on the clinical experience gained with study X-03016-3284 (LEIDA 2) and a meta- analysis of X-03016-3271 and X-03016-3284. The RMP is updated accordingly (version 3.2). C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data   | 10/11/2016   | 12/12/2016   | SmPC   | The product information was updated to include information on re-treating actinic keratosis lesions that have cleared after one or two courses of treatment and subsequently recur. If the treated area does not show complete clearance at a follow-up examination about 8 weeks after the last 4- weeks course of treatment, an additional 4-weeks course of Aldara treatment may be considered. A different therapy is recommended if the treated lesion(s) shows insufficient response to Aldara. Actinic keratosis lesions that have cleared after one or two courses of treatment and subsequently recur can be re- treated with one or two further courses of Aldara cream following an at least 12 weeks treatment pause. Please refer to section 5.1 of the Summary of Product Characteristics for more information.   |
|-----------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|--------------|--------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| N/0068    | Update of the package leaflet with revised contact details of the local representatives for Italy, Spain and France. Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                                                                             | 28/06/2016   | 12/12/2016   | PL     |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
| IA/0066   | B.I.b.1.c - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Addition of a new specification parameter to the specification with its corresponding test method                                                                                                                                             | 04/12/2015   | n/a          |        |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
| N/0065    | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                                                                                                                                                                                                  | 04/09/2015   | 18/02/2016   | PL     |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |

<div style=\"page-break-after: always\"></div>

| II/0063            | B.I.a.1.b - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Introduction of a manufacturer of the AS supported by an ASMF                                                                                                                   | 25/06/2015   | n/a        |                                  |                                   |
|--------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|------------|----------------------------------|-----------------------------------|
| IB/0064            | To update to QRD template 9 and to update the contact details of the local representative in Lithuania. In addition the MAH took this opportunity to make minor linguistic amendment. C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation | 04/02/2015   | 18/02/2016 | SmPC, Annex II, Labelling and PL |                                   |
| PSUSA/1729/ 201401 | Periodic Safety Update EU Single assessment - imiquimod                                                                                                                                                                                                                              | 11/09/2014   | n/a        |                                  | PRAC Recommendation - maintenance |
| II/0061            | C.I.13 - Other variations not specifically covered elsewhere in this Annex which involve the submission of studies to the competent authority                                                                                                                                        | 22/05/2014   | n/a        |                                  |                                   |
| N/0060             | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                                                                                                                     | 15/08/2013   | 18/02/2016 | PL                               |                                   |
| IA/0059/G          | This was an application for a group of variations. B.II.c.2.a - Change in test procedure for an excipient - Minor changes to an approved test procedure B.II.c.2.a - Change in test procedure for an excipient - Minor changes to an approved test procedure                         | 04/07/2013   | n/a        |                                  |                                   |
| IB/0058/G          | This was an application for a group of variations.                                                                                                                                                                                                                                   | 15/04/2013   | n/a        |                                  |                                   |

<div style=\"page-break-after: always\"></div>

|         | B.II.d.1.z - Change in the specification parameters and/or limits of the finished product - Other variation B.II.d.2.a - Change in test procedure for the finished product - Minor changes to an approved test procedure                                                                      |            |            |                        |                                                                                                                                                                                                                                                                          |
|---------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IG/0277 | C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation                                                                                                                                                                                                | 26/03/2013 | n/a        |                        |                                                                                                                                                                                                                                                                          |
| N/0056  | Update of the local representatives contact details for Romania, Slovenia, Ireland, Cyprus and Latvia. Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                       | 01/12/2011 | 18/02/2016 | PL                     |                                                                                                                                                                                                                                                                          |
| IA/0055 | A.4 - Administrative change - Change in the name and/or address of a manufacturer or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS                                                                                                         | 28/11/2011 | n/a        |                        |                                                                                                                                                                                                                                                                          |
| IA/0054 | B.II.b.1.a - Replacement or addition of a manufacturing site for the FP - Secondary packaging site                                                                                                                                                                                            | 12/11/2010 | n/a        |                        |                                                                                                                                                                                                                                                                          |
| II/0052 | Update of section 4.8 of the Summary of Product Characteristics (SmPC) to include additional information on safety in the paediatric population in line with the revised SmPC guideline, as requested by the CHMP. The Package Leaflet was updated accordingly. In addition, the MAH took the | 18/03/2010 | 27/04/2010 | SmPC, Labelling and PL | Aldara has been evaluated in four randomised, vehicle- controlled, double-blind trials in children aged 2 to 15 years with molluscum contaginosum (MC). Based on information from the above-mentioned studies and investigator-initiated studies in infants or children, |

<div style=\"page-break-after: always\"></div>

|         | opportunity to update section 4.4 of the SmPC to correct an error concerning the availability of data on long-term clearance rate for treatment of Superficial Basal Cell Carcinoma (sBCC), to implement the standard term \"Cutaneous Use\" instead of the previous \"For cutaneous use\" in the Labelling and to notify a change of the local representative in Malta in the Package Leaflet (PL). Update of Summary of Product Characteristics, Labelling and Package Leaflet   |            |            |                        | assessed within the procedure Aldara II-42, the adverse events which occurred more frequently in children receiving imiquimod were application site disorders and application site reactions. A review of the local skin reactions indicated no obvious difference in incidence or severity when compared to studies in adults, and this was reflected accordingly in section 4.8 of the SmPC. The data obtained from these studies in children did not indicate any differences in the safety profile compared to adults.   |
|---------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IA/0053 | B.II.b.1.a - Replacement or addition of a manufacturing site for the FP - Secondary packaging site                                                                                                                                                                                                                                                                                                                                                                             | 19/02/2010 | n/a        |                        |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
| IB/0049 | IB_41_a_02_Change in pack size - change in no. of units outside range of appr. pack size                                                                                                                                                                                                                                                                                                                                                                                       | 04/09/2009 | 04/09/2009 | SmPC, Labelling and PL |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
| IA/0051 | IA_09_Deletion of manufacturing site                                                                                                                                                                                                                                                                                                                                                                                                                                           | 03/09/2009 | n/a        |                        |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
| II/0046 | Update of Summary of Product Characteristics and Package Leaflet                                                                                                                                                                                                                                                                                                                                                                                                               | 23/07/2009 | 28/08/2009 | SmPC and PL            |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
| IA/0050 | IA_07_a_Replacement/add. of manufacturing site: Secondary packaging site                                                                                                                                                                                                                                                                                                                                                                                                       | 28/08/2009 | n/a        |                        |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
| IB/0048 | IB_13_b_Change in test proc. for active substance - other changes (replacement/addition)                                                                                                                                                                                                                                                                                                                                                                                       | 12/08/2009 | n/a        |                        |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |

<div style=\"page-break-after: always\"></div>

| R/0044   | Renewal of the marketing authorisation.                                                                                                                                                                                                                                                                                                                                                                                                                                                     | 26/06/2008   | 03/09/2008   | SmPC, Annex II, Labelling and PL   | Based on the review of the available information, the CHMP is of the opinion that the quality, safety and efficacy of this medicinal product continues to be adequately and sufficiently demonstrated and therefore considers that the benefit/risk profile of Aldara continues to be favourable.   |
|----------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|--------------|------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| II/0045  | Update of Summary of Product Characteristics, annex II and Package Leaflet To update section 4.8 of the SPC to include information on the post-marketing reports of cases of elevated liver enzymes as requested by the CHMP. Furthermore the MAH took the opportunity to update annex II to remove the condition to submit annual PSUR's. In addition the postal code for the manufacturing site was corrected in annex II and in the PL. Update of Summary of Product Characteristics and | 24/07/2008   | 03/09/2008   | SmPC, Annex II and PL              | Based on a review of the 26 case reports of hepatobiliary disorders out of which there were six serious case reports which suggested a causal relationship between imiquimod therapy and reports of elevated liver enzymes the Product Information was revised to reflect this information.         |
| II/0042  | To update sections 4.2 \"Posology and method of administration\", 5.1 \"Pharmacodynamic properties\" and 5.2 \"Pharmacokinetic properties\" of the SPC following evaluation of paediatric studies in the treatment of molluscum contagiosum, as requested by the CHMP in October 2007. On the basis of the information provided by the Marketing Authorisation Holder and as set out in the appended variation assessment report, the CHMP considers this variation to be a Type II variation.    | 30/05/2008   | 07/07/2008   | SmPC                               |                                                                                                                                                                                                                                                                                                     |

<div style=\"page-break-after: always\"></div>

|         | Update of Summary of Product Characteristics                                                                                                                                                                                                                                                                                                                                                                                                           |            |            |                        |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
|---------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| N/0041  | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                                                                                                                                                                                                                                                                                       | 15/02/2008 | n/a        | Labelling and PL       |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
| N/0040  | The Marketing Authorisation Holder (MAH) updated the list of local representatives in Greece, Portugal, Hungary, Czech Republic, Poland and Slovakia. Furthermore the MAH took this opportunity to correct a minor mistake in the numbering in of the points describing pictures in the German Package Leaflet. Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                       | 26/11/2007 | n/a        | PL                     |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
| T/0039  | Transfer of Marketing Authorisation                                                                                                                                                                                                                                                                                                                                                                                                                    | 02/08/2007 | 30/08/2007 | SmPC, Labelling and PL |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
| II/0038 | Quality changes                                                                                                                                                                                                                                                                                                                                                                                                                                        | 26/04/2007 | 03/05/2007 |                        |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
| II/0036 | Update of Summary of Product Characteristics and Package Leaflet To update sections 4.4 and 5.1 of the SPC to reflect four-year follow-up data from two clinical studies assessing recurrence rates of superficial basal cell carcinoma (sBCC). Additionally a warning in section 4.4 \"Special warnings and special precautions for use\" concerning the potential consequences of not allowing time for sufficient healing of the skin prior to Aldara | 22/03/2007 | 24/04/2007 | SmPC and PL            | On the basis of the observed results at the timepoint of the 48-month follow-up of two open-label studies evaluating the safety and long-term clinical efficacy of imiquimod 5% cream studies, the CHMP agreed to amend the statement in section 5.1 of the SPC regarding long-term clearance in sBCC . An estimated 79.3% [95% CI (73.7%-84.9%)] of all the subjects who initially received treatment became clinically clear and remained clear at 48 months, while data on recurrence rates beyond 48 months are not yet available. Further to the CHMP request following the assessment of |

<div style=\"page-break-after: always\"></div>

|         | administration was expanded as requested by CHMP in July 2006 following the evaluation of PSUR 10. The MAH also took the opportunity of this variation to correct translation errors in the Dutch, Greek and Norwegian Product Information (PI). Update of Summary of Product Characteristics and Package Leaflet                                                                                          |            |            |                                  | the 10th PSUR, to expand the following warning in section 4.4 \"Imiquimod cream therapy is not recommended until the skin has healed after any previous drug or surgical treatment\", the CHMP agreed on the additional statement in section 4.4 of the SPC saying that application of Aldara to broken skin could result in increased systemic absorption of imiquimod leading to a greater risk of adverse events.   |
|---------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|----------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IB/0037 | IB_13_b_Change in test proc. for active substance - other changes (replacement/addition)                                                                                                                                                                                                                                                                                                                   | 16/01/2007 | n/a        |                                  |                                                                                                                                                                                                                                                                                                                                                                                                                      |
| IB/0033 | IB_13_b_Change in test proc. for active substance - other changes (replacement/addition)                                                                                                                                                                                                                                                                                                                   | 19/12/2006 | n/a        |                                  |                                                                                                                                                                                                                                                                                                                                                                                                                      |
| IA/0035 | IA_13_a_Change in test proc. for active substance - minor change                                                                                                                                                                                                                                                                                                                                           | 14/12/2006 | n/a        |                                  |                                                                                                                                                                                                                                                                                                                                                                                                                      |
| IA/0034 | IA_13_a_Change in test proc. for active substance - minor change                                                                                                                                                                                                                                                                                                                                           | 14/12/2006 | n/a        |                                  |                                                                                                                                                                                                                                                                                                                                                                                                                      |
| II/0026 | Extension of Indication To update of section 4.1 \"Therapeutic indications\" of the Summary of Products Characteristics (SPC) to extend the current approved indications to the treatment of actinic keratosis (AKs). Consequently sections 4.2 \"Posology and method of administration\", 4.4 \"Special warnings and precautions for use\", 4.8 \"Undesirable effects\", 5.1 \"Pharmacodynamic properties\" and 5.2 | 18/10/2006 | 29/11/2006 | SmPC, Annex II, Labelling and PL | Please refer to the Scientific Discussion: Aldara-H-179-II- 26-AR                                                                                                                                                                                                                                                                                                                                                    |

<div style=\"page-break-after: always\"></div>

|         | \"Pharmacokinetic properties\" of the SPC have been updated. Furthermore, following a review on adverse reactions, section 4.8 was updated to introduce alopecia, reduction in haematological parameters requiring clinical intervention and dermatological drug reactions. The Package Leaflet (PL) has been updated accordingly. The MAH took the opportunity to update the annexes according to the latest QRD templates. Additionally, the package leaflet has been amended following user testing results. The MAH also took the opportunity of this change to amend the list of local representatives for Iceland, the Netherlands, and Estonia and to correct a number of errors in the translations that have been identified in all languages except Czech.   |            |            |      |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
|---------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| II/0031 | To update sections 4.4 \"Special warnings and special precautions for use\" and 5.1 \"Pharmacodynamic properties\" of the Summary of Product Characteristics to reflect a three year follow up data following evaluation of two clinical studies, assessing recurrence rates of specified basal cell carcinomas, as requested by CHMP in May 2006. Update of Summary of Product Characteristics                                                                                                                                                                                                                                                                                                                                                                          | 27/07/2006 | 01/09/2006 | SmPC | The indication for the topical treatment of superficial basal cell carcinoma (sBCC) in adult patients was granted in 2004. The clinical trial programme for this indication included two ongoing long-term phase III studies to assess recurrence rates of sBCCs up to five years after treatment with imiquimod 5% cream, 5x/week (study 1412-IMIQ) or 7x/week (study 1413-IMIQ) for 6 weeks. The MAH committed to submit results from these studies at yearly intervals and at the end of the five-year follow-up period. With this variation the MAH updated the SPC based on the second of the interim reports for studies 1412 and 1413, |

<div style=\"page-break-after: always\"></div>

<!-- image -->

|         |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |            |            |             | reporting 3-year follow-up data.These data show that an estimated 80.5% [95% CI (75.4%, 85.6%)] of all the subjects who initially received treatment became clinically clear and remained clear at 36 months.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
|---------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IA/0032 | IA_13_a_Change in test proc. for active substance - minor change                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | 16/08/2006 | n/a        |             |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| IA/0030 | IA_07_a_Replacement/add. of manufacturing site: Secondary packaging site                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         | 16/06/2006 | n/a        |             |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| II/0027 | To update sections 4.4 and 4.5 of the SPC to include a warning for patients who are receiving immunosuppressive medication for (auto)immune conditions, following the evaluation of the PSUR 9. Furthermore, following concerns stated in the evaluation of the PSUR 9 the MAH requested to update section 4.4 to include a sentence to avoid the contact with the lips and nostrils and to remove a statement regarding limited use in patients older than 65. Additionally, the MAH took the opportunity of this variation to include in section 4.4 a recommendation for interruption of dosing in the event of flu-like symptoms. Section 2 of the PL was revised to include a warning regarding use near the eyes, lips and nostrils. The MAH also took the opportunity of this variation to correct translation errors in the Spanish, French and Italian SPC, Dutch, Swedish and Hungarian SPC and PL and in the Lithuanian, Slovakian and Slovenian PL. Update of Summary of Product Characteristics and | 23/03/2006 | 27/04/2006 | SmPC and PL | Precautions for use in patients with autoimmune conditions: following the evaluation of PSUR 9 (covering the period from 27 February 2004 to 26 February 2005), the MAH submitted this type II variation to update section 4.4 and 4.5 to warn prescribers to exercise caution when treating patients who are receiving immunosuppressive medication for (auto)immune conditions and advise balancing the benefit of imiquimod treatment with the potential risks for these patients. Furthermore, section 4.8 of the SPC was updated to state that rare reports have been received of exacerbation of autoimmune conditions. Precautions for use in organ transplant patients: the systemic concentration of Aldara is likely to be very low in the majority of patients. However, remains a theoretical chance that it attenuates the action of immuno- suppressants. Since graft-versus-host disease and the rejection of an organ are potentially life-threatening adverse effects, and since immuno-suppressed patients are more likely to require imiquimod therapy, it is important that prescribers are made aware of this and of the need to base imiquimod treatment on a careful benefit-risk |

<div style=\"page-break-after: always\"></div>

|         | Package Leaflet                                                                                                                                                                                                                                          |            |            |                  | assessment. Section 4.4 of the SPC was updated to reflect this information. Precautions for use near the eyes and nose: based on a review of all reactions that have occurred where Aldara was administered close to the eyes, nose, lips and hairline the warning in section 4.4 of the SPC and in section 2 of the PL to \"avoid contact with the eyes\" was extended to the lips and nostrils. Furthermore, an advice was introduced in section 2 of the PL on what action to take in the event that Aldara is accidentally applied to the eyes, lips and nostrils. Precautions for use in patients older than 65 years: since a large number of patients over the age of 65 years have been studied in clinical trials for sBCC and for actinic keratoses the statement regarding limited use in patients older than 65 was removed from section 4.4 of the SPC. P   |
|---------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| N/0028  | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                                                                                         | 19/12/2005 | n/a        | Labelling and PL |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
| II/0025 | Update of Summary of Product Characteristics and Package Leaflet                                                                                                                                                                                         | 15/09/2005 | 28/10/2005 | SmPC and PL      |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
| IA/0024 | IA_07_a_Replacement/add. of manufacturing site: Secondary packaging site                                                                                                                                                                                 | 30/11/2004 | n/a        |                  |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
| N/0023  | To update the list of local representatives in Austria, Cyprus, Finland, Germany, Iceland, the Netherlands, Norway and Portugal in the Package Leaflet. Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification) | 11/10/2004 | n/a        | PL               |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |

<div style=\"page-break-after: always\"></div>

| IA/0022   | IA_07_a_Replacement/add. of manufacturing site: Secondary packaging site                       | 12/08/2004   | n/a        |                                  |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
|-----------|------------------------------------------------------------------------------------------------|--------------|------------|----------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| II/0020   | Extension of Indication                                                                        | 03/06/2004   | 13/07/2004 | SmPC and PL                      | The Marketing Authorisation Holder (MAH) applied for the extension of the therapeutic indication to include patients with superficial basal cell carcinoma. Furthermore, the MAH took the opportunity of the variation to update section 4.8 (\"Undesirable effects\") according to MedDRA, following a request from the CPMP in July 2003. The Package Leaflet (PL) has been revised accordingly. In addition, the MAH completed the list of local representatives in the PL to include the 10 new EU Member States and changed the format according to the latest EMEA/QRD template. Please refer to the Scientific Discussion: Aldara-H-179-II- 20. |
| IA/0021   | IA_38_a_Change in test procedure of finished product - minor change to approved test procedure | 26/02/2004   | n/a        |                                  |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
| II/0018   | Update of Summary of Product Characteristics and Package Leaflet                               | 25/09/2003   | 27/01/2004 | SmPC and PL                      | To update the SPC section 5.1 \"Pharmacodynamic properties\" to include information on median time to clearance and percentage of patients who achieved total clearance of their warts. Relevant changes are equally proposed for the PL.                                                                                                                                                                                                                                                                                                                                                                                                              |
| R/0017    | Renewal of the marketing authorisation.                                                        | 24/07/2003   | 24/10/2003 | SmPC, Annex II, Labelling and PL |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
| II/0015   | Update of Summary of Product Characteristics and Package Leaflet                               | 19/03/2003   | 26/06/2003 | SmPC and PL                      | To update the SPC section 4.2 \" Posology and method of administration\" to include information on safety beyond 16 weeks and section 4.4 \"Special warnings and special                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |

<div style=\"page-break-after: always\"></div>

|         |                                                                  |            |            |                        | precautions for use\" to include information on repeat treatment following the availability of new clinical data. Relevant changes are equally proposed for the PL.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
|---------|------------------------------------------------------------------|------------|------------|------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| II/0016 | Update of Summary of Product Characteristics                     | 20/02/2003 | 13/06/2003 | SmPC                   | To update the SPC section 4.6 \" Pregnancy and Lactation\" to reflect new information on usage during pregnancy following the availability of new post marketing information.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
| II/0014 | Update of Summary of Product Characteristics and Package Leaflet | 20/02/2003 | 13/06/2003 | SmPC and PL            | To update the SPC, sections 4.2 \"Posology and method of administration\" to strengthen dosage and usage instructions, 4.4 \"Special warnings and special precautions for use\" and 4.8 \"Undesirable Effects\" to include warnings about the severity of application site reactions and warnings about female urinary symptoms following the CPMP assessment of Periodic Safety Update Report (PSUR) 6 covering the period 27 February 2001 - 26 February 2002. In addition, the MAH proposed to slightly amend section 4.4 regarding advice to uncircumcised men and sections 4.8 and 5.1 \"Pharmacodynamic properties\" concerning the likely application site reactions as a consequence of the mode of action. Finally the MAH amended section 6.4 \" Special precautions for storage\" to indicate that sachets should not be reused once opened. Relevant changes are equally proposed for the PL. In addition, the list of local representatives in the PL has been revised. |
| II/0012 | Update of Summary of Product Characteristics and Package Leaflet | 26/07/2001 | 21/11/2001 | SmPC, Labelling and PL |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
| I/0013  | 15a_Change in IPCs applied during the manufacture                | 14/05/2001 | 23/05/2001 |                        |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |

<div style=\"page-break-after: always\"></div>

|         | of the product                                                                                   |            |            |                  |
|---------|--------------------------------------------------------------------------------------------------|------------|------------|------------------|
| I/0011  | 04_Replacement of an excipient with a comparable excipient                                       | 27/10/2000 | 14/11/2000 |                  |
| I/0010  | 04_Replacement of an excipient with a comparable excipient                                       | 27/10/2000 | 14/11/2000 |                  |
| II/0008 | Change(s) to shelf-life or storage conditions                                                    | 21/09/2000 | 27/10/2000 |                  |
| N/0009  | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification) | 09/06/2000 | 01/08/2000 | PL               |
| I/0006  | 25_Change in test procedures of the medicinal product                                            | 25/05/2000 | n/a        |                  |
| I/0005  | 25_Change in test procedures of the medicinal product                                            | 25/05/2000 | n/a        |                  |
| I/0004  | 25_Change in test procedures of the medicinal product                                            | 25/05/2000 | n/a        |                  |
| I/0007  | 01_Change in or addition of manufacturing site(s) for part or all of the manufacturing process   | 06/04/2000 | 11/04/2000 |                  |
| I/0003  | 25_Change in test procedures of the medicinal product                                            | 06/04/2000 | 11/04/2000 |                  |
| N/0002  | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification) | 19/12/1999 | 09/03/2000 | Labelling and PL |

<div style=\"page-break-after: always\"></div>

| I/0001   | 12_Minor change of manufacturing process of the active substance   | 16/12/1999   | n/a   |
|----------|--------------------------------------------------------------------|--------------|-------|